MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-01-2025
Blueprint Medicines Corporation Cash Conversion Cycle 2011-2026 | BPMC
Annual Cash Conversion Cycle Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 254 | 978 | 458 | 213 | -248 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 978 | -248 | 331 |
Quarterly Cash Conversion Cycle Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 356 | - | 473 | 264 | 657 | - | 382 | 385 | 526 | - | 485 | 150 | 270 | - | 328 | 287 | 7.85 K | - | 2.63 K | 3.1 K | -1.05 K | 1.17 | 6.62 | 11.8 | 45.4 | 5.65 | 5.33 | 0.07 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.85 K | -1.05 K | 747 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M |  USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.89 | -0.61 % | $ 6.54 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
257 | $ 22.57 | 1.21 % | $ 3.74 B | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
52.4 | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
11.9 | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
-51.6 | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.09 | -0.37 % | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 23.2 | -0.96 % | $ 2.95 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.48 | 3.87 % | $ 394 M | Britain |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |
 |
ContraFect Corporation
CFRX
|
-1.83 K | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.71 | -0.58 % | $ 114 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-216 | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-32.5 K | $ 1.07 | -1.83 % | $ 13.1 M | USA |